BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Proteinuric diabetic kidney disease frequently progresses to ESRD. Control of BP delays progression, but the optimal BP to improve outcomes remains unclear. The objective of this analysis was to evaluate the relationship between BP and renal outcomes in proteinuric diabetic kidney disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: BP data from all 1448 randomized participants in the Veterans Affairs Nephropathy in Diabetes Trial were included in a post hoc analysis. The associations of mean on-treatment BP with the primary end point (decline in eGFR, ESRD, or death), renal end point (decline in eGFR or ESRD), rate of eGFR decline, and mortality were measured. RESULTS: The median (25th, 75th percentile) follow-up time was 2.2 (1.2, 3.0) years. There were 284 primary end points. In univariate analyses, both mean systolic and mean diastolic BPs were strongly associated (P<0.001) with the primary end point. After multivariate adjustment, the hazard of developing the primary end point became progressively higher as mean systolic BP rose from <120 to ≥ 150 mmHg (P=0.02), with a significantly higher hazard ratio for 140-149 versus 120-129 mmHg (1.51 [1.06, 2.15]; P=0.02). There was also a significant association of mean diastolic BP with the hazard of developing the primary end point (P<0.01), with a significantly higher hazard ratio when mean diastolic BP was 80-89 versus 70-79 mmHg (1.54 [1.05, 2.25]; P=0.03); there was also a strong trend when mean diastolic BP was <60 mmHg. Associations between BP and both renal end point and rate of eGFR decline were similar to those with the primary end point. No association of BP with mortality was observed, possibly because of the limited number of mortality events. CONCLUSIONS: In patients with proteinuric diabetic kidney disease, mean systolic BP ≥ 140 mmHg and mean diastolic BP ≥ 80 mmHg were associated with worse renal outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypertension is a strong risk factor for the development and progression of CKD (66).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypertension is a strong risk factor for the development and progression of CKD (67).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [67]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Once diagnosed with hypertension, an individual is 2.5 times more likely to be diagnosed with T2D within the next 5 years.181,182”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [181]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hypertension is not only more prevalent in persons with T2D than in the general population, but hypertension also predicts progression to T2D.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [181]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Research works printed but not linked: 2
- US Renal Data System : USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013 [Google Scholar]
- Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group : KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2: 337–414, 2012 [Google Scholar]
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
“Hypertension is a strong risk factor for the development and progression of CKD (78).”
Background11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 302
“development and progression of diabetic kidney disease (48).”
Background11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 275
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Pathomechanisms of Diabetic Kidney Disease
Sinha, S. K., & Nicholas, S. B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237349 · Cited by 115
“Early studies suggested a combination of ACE inhibitors and ARB may provide additional benefits in diabetic nephropathy [139,140], however, this combination is not clinically recommended due to complications of hyperkalemia and acute kidney injury.”
BackgroundXie, D., Ma, T., Cui, H., Li, J., Zhang, A., Sheng, Z., & Xie, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-47091-y · Cited by 80
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Gu, J., Yang, M., Qi, N., Mei, S., Chen, J., Song, S., Jing, Y., Chen, M., He, L., Sun, L., et al. (2016) · Kidney & Blood Pressure Research · doi:10.1159/000452588 · Cited by 54
Yuhong, H., Shi, R., Mo, R., & Hu, F. (2020) · Aging · doi:10.18632/aging.103259 · Cited by 47
“Leehey et al [40] confirmed that DN patients with mean SBP ≥140 mmHg had poor renal prognosis. www.aging-us.com 10326 AGING The cause of hypertension in diabetes mellitus patients may be associated with DN pathogenesis with small artery pressure causing renal arteriolar sclerosis, hemal wall thickening, luminal narrow…”
BackgroundScheen, A. J., & Delanaye, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.12.010 · Cited by 47
“Affairs Nephropathy in Diabetes Study (NEPHRON-D) [66]; Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) [67]; and Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial (ORIENT) [68,69].”
BackgroundCosmo, S. D., Viazzi, F. C., Piscitelli, P. A., Giorda, C. B., Ceriello, A., Genovese, S., Russo, G. T., Guida, P., Fioretto, P., & Pontremoli, R. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001045 · Cited by 40
Lewinski, A. A., Patel, U. D., Diamantidis, C. J., Oakes, M. M., Baloch, K. N., Crowley, M. J., Wilson, J. A., Pendergast, J., Biola, H. R., Boulware, L. E., et al. (2019) · Journal of Medical Internet Research · doi:10.2196/12541 · Cited by 36
for the Japanese Study Group of Kidney Disease in Children (JSKDC), Shima, Y., Nakanishi, K., Sako, M., Saito-Oba, M., Hamasaki, Y., Hataya, H., Honda, M., Kamei, K., Ishikura, K., et al. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-4099-8 · Cited by 30
Brosnahan, G., Abebe, K. Z., Moore, C. G., Bae, K. T., Braun, W. E., Chapman, A. B., Flessner, M. F., Harris, P. C., Hogan, M. C., Perrone, R. D., et al. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180322110209 · Cited by 28
Li, L., Chen, L., Zhang, C., Gui, S., Zhao, H., & Li, Z. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8554 · Cited by 31
“Diabetic nephropathy (DN) is the most severe complication of diabetes and is also a major contributor to end‐stage renal failure (4).”
BackgroundZhao, L., Li, L., Ren, H., Zou, Y., Zhang, R., Wang, S., Xu, H., Zhang, J., & Liu, F. (2020) · Renal Failure · doi:10.1080/0886022x.2020.1804402 · Cited by 24
Self-citationNatale, P., Palmer, S. C., Navaneethan, S. D., Craig, J. C., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006257.pub2 · Cited by 39
Diabetic Kidney Disease Prevention Care Model Development
ElSayed, N. A., Bannuru, R. R., Bakris, G. L., Bardsley, J. K., de Boer, I. H., Gabbay, R. A., Gockerman, J. P., McCoy, R. G., McCracken, E., Neumiller, J. J., et al. (2023) · Clinical Diabetes · doi:10.2337/cd23-0063 · Cited by 26
Zhao, L., Liu, F., Li, L., Zhang, J., Wang, T., Zhang, R., Zhang, W., Yang, X., Zeng, X., Wang, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83856-z · Cited by 19
Self-citationShi, C., Wan, Y., He, A., Wu, X., Shen, X., Zhu, X., Yang, J., & Zhou, Y. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02094-z · Cited by 17
hsa_circ_0071106 can be used as a diagnostic marker for type 2 diabetes
Yingying, Z., Yongji, Y., Qiuting, C., Rifang, L., & Zhuanping, Z. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.52575 · Cited by 17
“According to the International Diabetes Federation (IDF) Diabetes Atlas (9th Edition, 2019), nearly 463 million diabetic patients exist worldwide, 1 in 2 adults with diabetes are undiagnosed [1].”
MethodZiff, O. J., Covic, A. C., & Goldsmith, D. J. A. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12803 · Cited by 14
Woodhams, L., Sim, T. F., Chalmers, L., Yeap, B. B., GREEN, D. J., Schlaich, M. P., Schultz, C. J., & Hillis, G. S. (2021) · PeerJ · doi:10.7717/peerj.11070 · Cited by 16
“Findings regarding the benefits of reductions in DBP are conflicting (Alwakeel et al., 2011; Leehey et al., 2015).”
BackgroundSchultes, B., Emmerich, S., Kistler, A. D., Mecheri, B., Schnell, O., & Rudofsky, G. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211054520 · Cited by 12
“To investigate the utilization purpose and relevance of ACR POCT, physicians were asked to fill out a questionnaire with the two following questions: (1) “For what purpose do you use the ACR POCT value?” and (2) “How important is the ACR POCT value for you?” Multiple responses were possible.”
BackgroundMethodInfluentialAvula, A., Johal, L. K., Ali, F., Amir, S., Yadav, S. K., Murtuza, M., Zia, U., Janjua, F. F., Raza, A. A., Lal, K., et al. (2025) · Cureus · doi:10.7759/cureus.93707 · Cited by 13
“Conversely, the absence of safety events in our patient contrasts sharply with the higher rates of hyperkalemia and AKI in the VA NEPHRON-D population analyzed by Leehey et al. (2015) [15], where the combination of ACEi+ARB was associated with increased adverse events.”
Blood Pressure Parameters and their Associations with Death in Patients with Chronic Kidney Disease
Qureshi, S., Lorch, R., & Navaneethan, S. D. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0790-6 · Cited by 9
Zuo, Y., Li, T., & Lei, Z. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104286 · Cited by 9
Fıcı, F., Arı, E., Yüce, E. İ., Kanuncu, S., Makel, W., Tarım, B. A., & Robles, N. R. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00358-1 · Cited by 13
Intensive Home Blood Pressure Lowering in Patients With Advanced CKD
Ku, E., Copeland, T. P., McCulloch, C. E., Seth, D., Carlos, C. A., Cho, K., Malkina, A., Lo, L. J., & Hsu, R. K. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.08.010 · Cited by 10
Mu, H., Zhang, Q., Huang, W., Pan‐Hammarström, Q., Zhang, Y., Lu, Y., Zhu, Z., Jiang, X., Wang, G., Zheng, M., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1584049 · Cited by 13
Li, J.-C., Tian, J., Wu, S., Wang, Z., Zhang, X., Jia, D., Ding, R.-J., Xiao, X.-F., Fan, Y., & Hu, D. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.231528 · Cited by 8
Yang, C.-C., Lin, C.-H., Wang, N., Lai, C., Lo, F., & The Chang Gung Juvenile Diabetes Eye Study Group (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00429 · Cited by 9
“Hypertension is a strong risk factor for the development and progression of diabetic kidney disease (26).”
BackgroundGuo, J., Wei, M., Zhang, W., Jiang, Y., Li, A., Wang, C., Yin, D., Sun, A., & Gong, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1517272 · Cited by 9
Cardiac Effects of Renin-Angiotensin System Inhibitors in Nonproteinuric CKD
Shulman, R. S., Yang, W. P., Cohen, D. L., Reese, P. P., Cohen, J. B., & the CRIC Study Investigators (2024) · Hypertension · doi:10.1161/hypertensionaha.124.23184 · Cited by 7
Nicholas, S. B., & Tuttle, K. R. (2020) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2020.19.2.5 · Cited by 6
Zhou, Y., Chang, D., Li, J., Shan, Y., Huang, X., Zhang, F., Luo, Q., Xiong, Z., Zhao, M., Hou, S., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109978 · Cited by 5
Blood Pressure–Related Outcomes in a Diabetic Population
Whaley‐Connell, A. T., & Sowers, J. R. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07439 · Cited by 5
Self-citationChen, Y.-X., Hu, D.-S., Lin, M.-X., Gao, Z.-H., Hong, H.-Z., Hu, Y., Yao, L., Cui, G.-W., & Wang, L. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2472981 · Cited by 7
“These circumstances exacerbate the progression of T2DKD [27].”
Wang, Y., Liu, T., Li, N., Zhao, T., Wu, X., Wang, Y., Dong, X., Zhao, H., Liu, W. J., & Li, P. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/9987648 · Cited by 3
“Renal outcomes tend to be worse when the mean systolic blood pressure is at least 140 mmHg and the mean diastolic blood pressure is at least 80 mmHg [46].”
Sudoscan's Effectiveness in Identifying Chronic Kidney Disease in Patients With Type 2 Diabetes
Nica, A. E., Rusu, E., Dobjanschi, C. G., Rusu, F., Parlițeanu, O. A., Vinereanu, I.-V., Sivu, C., & Radulian, G. (2024) · Cureus · doi:10.7759/cureus.60344 · Cited by 4
“…progression of CKD. Antihypertensive therapy reduces the risk of albuminuria, and in individuals with T2DM and stabilized CKD (eGFR), angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy reduces the risk of progression to end-stage kidney disease [18-20].”
BackgroundWalther, C. P., Chandra, A., & Navaneethan, S. D. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000375 · Cited by 3
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30106-8 · Cited by 2
Mehdiyev, S. K., Мустафаев, И. И., & Мамедов, М. Н. (2019) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2019-3-48-56 · Cited by 1
The Secret Side of the Military and the Kidney
Zuber, K., & Ho, R. (2022) · Physician Assistant Clinics · doi:10.1016/j.cpha.2021.11.012 · Cited by 1
Verminderung der Progression einer chronischen Niereninsuffizienz
Sollinger, D., Schamberger, B., Weinmann‐Menke, J., & Lutz, J. (2016) · Der Nephrologe · doi:10.1007/s11560-016-0076-z · Cited by 1
Alicic, R. Z., & Tuttle, K. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00037-8 · Cited by 1
Stanton, R. C. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_2 · Cited by 2
Conte, C., & Secchi, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00023-x
Tratamento hipertensivo nefroprotetor
Coelho, C. C., de Araújo, A. C. M., Alves, I. C. S., Natividade, T. D. S. S., & de Lima, A. B. (2020) · Pará Research Medical Journal · doi:10.4322/prmj.2019.038
Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes
Hahr, A. J., & Molitch, M. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_23
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00039-6
Arablinsky, N. A., Анатольевна, Ф. Д., Metelskaya, V. A., Timofeev, Y. S., Shukurov, F. B., Taliuridze, M. T., Vasiliev, D. K., & Drapkina, O. M. (2025) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-4210
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Metadata
- Authors
- Leehey, D. J., Zhang, J. H., Emanuele, N. V., Whaley-Connell, A., Palevsky, P. M., Reilly, R. F., Guarino, P., & Fried, L. F.
- Affiliations
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- Corresponding author
- Leehey, David J.
- Emanuele, Nicholas V.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2015-12
- Volume
- 10
- Issue
- 12
- Pages
- 2159-2169
- ISSN
- 1555-9041 (ISSN-L)
- PMC
- PMC4670761
- OpenAlex
- W1880991675
- Semantic Scholar
- 4ada66d1848bcba4f438c95df9007e6e5d850587
- Cited by
- 62
- References
- 37
- Citations by year
- 2025: 8 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 7 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 1
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- blood pressure, diabetic nephropathy, proteinuria, end-stage renal disease, estimated glomerular filtration rate decline, systolic blood pressure, diastolic blood pressure, renal outcomes, mortality, veterans
- MeSH terms
- Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Hypertension, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Risk Factors, Time Factors, United States, United States Department of Veterans Affairs, Multivariate Analysis, Proportional Hazards Models, Treatment Outcome, Lisinopril, Disease Progression, Losartan, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.